CASIRIVIMAB\IMDEVIMAB vs CEFEPIME: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
CASIRIVIMAB\IMDEVIMAB vs CEFEPIME: Safety Overview
| Metric | CASIRIVIMAB\IMDEVIMAB | CEFEPIME |
|---|---|---|
| Total FAERS Reports | 4,248 | 5,540 |
| Deaths Reported | 137 | 997 |
| Death Rate | 3.2% | 18.0% |
| Hospitalizations | 1,351 | 3,055 |
| Average Patient Age | 54.3 yrs | 56.5 yrs |
| % Female Patients | 55.4% | 47.6% |
| FDA Approval Date | N/A | Aug 21, 2018 |
| Manufacturer | N/A | Apotex Corp. |
| Route | N/A | INTRAMUSCULAR |
| Marketing Status | N/A | Discontinued |